从动脉粥样硬化冠状动脉中分离出的肺炎衣原体菌株的体外药敏性。
In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries.
作者信息
Gieffers J, Solbach W, Maass M
机构信息
Institute of Medical Microbiology and Hygiene, Medical University of Lübeck, D-23538 Lübeck, Germany.
出版信息
Antimicrob Agents Chemother. 1998 Oct;42(10):2762-4. doi: 10.1128/AAC.42.10.2762.
Abstract
Chlamydia pneumoniae strains have been recovered from arteriosclerotic coronary arteries, but their antibiotic susceptibility profiles have not yet been examined. We report in vitro susceptibility data for five cardiovascular C. pneumoniae isolates. These strains did not differ significantly from respiratory strains in their patterns of susceptibility to azithromycin, erythromycin, roxithromycin, ofloxacin, doxycycline, rifampin, and penicillin G. Roxithromycin was the most active macrolide, and rifampin was the most effective drug overall.
摘要
肺炎衣原体菌株已从动脉粥样硬化的冠状动脉中分离出来，但它们的抗生素敏感性谱尚未得到检测。我们报告了五株心血管肺炎衣原体分离株的体外药敏数据。这些菌株在对阿奇霉素、红霉素、罗红霉素、氧氟沙星、强力霉素、利福平和青霉素G的敏感性模式上与呼吸道菌株没有显著差异。罗红霉素是活性最强的大环内酯类药物，总体上利福平是最有效的药物。
相似文献
1
In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries.从动脉粥样硬化冠状动脉中分离出的肺炎衣原体菌株的体外药敏性。
Antimicrob Agents Chemother. 1998 Oct;42(10):2762-4. doi: 10.1128/AAC.42.10.2762.
2
In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations.德国患者肺炎衣原体分离株的体外药敏性及抗生素联合用药的协同活性。
Antimicrob Agents Chemother. 1999 Jul;43(7):1808-10. doi: 10.1128/AAC.43.7.1808.
3
In vitro activity of trovafloxacin against Chlamydia pneumoniae.曲伐沙星对肺炎衣原体的体外活性。
Antimicrob Agents Chemother. 1997 Sep;41(9):2033-4. doi: 10.1128/AAC.41.9.2033.
4
In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.阿奇霉素、克拉霉素、左旋氧氟沙星及其他抗生素对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1992 Jul;36(7):1573-4. doi: 10.1128/AAC.36.7.1573.
5
Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease.在冠状动脉疾病中，血管内存在存活的肺炎衣原体是一种常见现象。
J Am Coll Cardiol. 1998 Mar 15;31(4):827-32. doi: 10.1016/s0735-1097(98)00016-3.
6
In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells.肺炎衣原体心血管菌株对冠状动脉内皮细胞和平滑肌细胞的体外敏感性及清除情况。
Cardiovasc Drugs Ther. 2001;15(3):259-62. doi: 10.1023/a:1011972424529.
7
Isolation of Chlamydophila pneumoniae from atheromas of the carotid artery and their antibiotics susceptibility profile.从颈动脉粥样硬化斑块中分离出肺炎衣原体及其抗生素敏感性分析。
Enferm Infecc Microbiol Clin. 2006 Feb;24(2):81-5. doi: 10.1157/13085013.
8
In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae.新型酮内酯类药物泰利霉素对肺炎衣原体的体外活性
J Antimicrob Chemother. 2001 Sep;48(3):403-5. doi: 10.1093/jac/48.3.403.
9
Detection of Chlamydia pneumoniae DNA in the coronary arteries and bypass in three patients with diffuse coronary artery disease.在三名弥漫性冠状动脉疾病患者的冠状动脉和搭桥血管中检测肺炎衣原体DNA。
Cardiology. 2005;103(3):121-2. doi: 10.1159/000083436. Epub 2005 Jan 19.
10
In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.新型酮内酯类抗生素HMR 3647对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1998 Jun;42(6):1515-6. doi: 10.1128/AAC.42.6.1515.
引用本文的文献
1
Persistence of obligate intracellular pathogens: alternative strategies to overcome host-specific stresses.专性细胞内病原体的持续存在：克服宿主特异性应激的替代策略。
Front Cell Infect Microbiol. 2023 May 22;13:1185571. doi: 10.3389/fcimb.2023.1185571. eCollection 2023.
2
The Genetic Transformation of Chlamydia pneumoniae.肺炎衣原体的基因转化。
mSphere. 2018 Oct 10;3(5):e00412-18. doi: 10.1128/mSphere.00412-18.
3
Chlamydia pneumoniae induces aponecrosis in human aortic smooth muscle cells.肺炎衣原体可诱导人主动脉平滑肌细胞发生凋亡性坏死。
BMC Microbiol. 2005 Jan 21;5:2. doi: 10.1186/1471-2180-5-2.
4
Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae.GyrA基因中的丝氨酸到天冬酰胺的替换导致暴露于莫西沙星的肺炎衣原体对喹诺酮耐药。
Antimicrob Agents Chemother. 2005 Jan;49(1):406-7. doi: 10.1128/AAC.49.1.406-407.2005.
5
Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.替利霉素治疗C57BL/6J小鼠慢性肺炎衣原体感染
Antimicrob Agents Chemother. 2004 Oct;48(10):3655-61. doi: 10.1128/AAC.48.10.3655-3661.2004.
6
Antibody levels against Chlamydia pneumoniae and outcome of roxithromycin therapy in patients with acute myocardial infarction. Results from a sub-study of the randomised Antibiotic Therapy in Acute Myocardial Infarction (ANTIBIO) trial.急性心肌梗死患者抗肺炎衣原体抗体水平及罗红霉素治疗效果。急性心肌梗死抗生素治疗（ANTIBIO）随机试验子研究结果。
Z Kardiol. 2004 Sep;93(9):671-8. doi: 10.1007/s00392-004-0113-1.
7
Culture-negative endocarditis due to Chlamydia pneumoniae.肺炎衣原体所致的血培养阴性的心内膜炎
J Clin Microbiol. 2002 Feb;40(2):718-20. doi: 10.1128/JCM.40.2.718-720.2002.
8
Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.肺炎衣原体与动脉粥样硬化：诊断方法的批判性评估及其与治疗研究的相关性
Clin Microbiol Rev. 2002 Jan;15(1):1-20. doi: 10.1128/CMR.15.1.1-20.2002.
本文引用的文献
1
Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease.在冠状动脉疾病中，血管内存在存活的肺炎衣原体是一种常见现象。
J Am Coll Cardiol. 1998 Mar 15;31(4):827-32. doi: 10.1016/s0735-1097(98)00016-3.
2
Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.阿奇霉素对成人和儿童社区获得性肺炎患者肺炎衣原体分离株的微生物学疗效及肺炎衣原体分离株对阿奇霉素的敏感性
Antimicrob Agents Chemother. 1998 Jan;42(1):194-6. doi: 10.1128/AAC.42.1.194.
3
Cardiovascular disease risk from prior Chlamydia pneumoniae infection can be related to certain antigens recognized in the immunoblot profile.既往肺炎衣原体感染导致的心血管疾病风险可能与免疫印迹图谱中识别的某些抗原有关。
J Infect. 1997 Sep;35(2):171-6. doi: 10.1016/s0163-4453(97)91743-6.
4
Endovascular presence of Chlamydia pneumoniae in patients with hemodynamically effective carotid artery stenosis.血流动力学有效的颈动脉狭窄患者体内肺炎衣原体的血管内存在情况。
Angiology. 1997 Aug;48(8):699-706. doi: 10.1177/000331979704800805.
5
Chronic infections and coronary heart disease: is there a link?慢性感染与冠心病：存在关联吗？
Lancet. 1997 Aug 9;350(9075):430-6. doi: 10.1016/S0140-6736(97)03079-1.
6
Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group.罗红霉素治疗非Q波冠状动脉综合征的随机试验：ROXIS初步研究。ROXIS研究组
Lancet. 1997 Aug 9;350(9075):404-7. doi: 10.1016/s0140-6736(97)07201-2.
7
Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction.心肌梗死男性幸存者中肺炎衣原体抗体升高、心血管事件与阿奇霉素
Circulation. 1997 Jul 15;96(2):404-7. doi: 10.1161/01.cir.96.2.404.
8
Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen.从颈动脉内膜切除术标本中分离出肺炎衣原体。
J Infect Dis. 1997 Jul;176(1):292-5. doi: 10.1086/517270.
9
Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group.从一名冠状动脉粥样硬化患者的冠状动脉中分离出肺炎衣原体。肺炎衣原体/动脉粥样硬化研究小组。
Ann Intern Med. 1996 Dec 15;125(12):979-82. doi: 10.7326/0003-4819-125-12-199612150-00008.
10
Evaluation of culture conditions used for isolation of Chlamydia pneumoniae.用于分离肺炎衣原体的培养条件评估。
Am J Clin Pathol. 1995 Feb;103(2):141-8. doi: 10.1093/ajcp/103.2.141.
Zotero 插件